Negative correlation between acetyl-CoA acyltransferase 2 and cetuximab resistance in colorectal cancer

The emergence of anti-EGFR therapy has revolutionized the treatment of colorectal cancer (CRC). However, not all patients respond consistently well. Therefore, it is imperative to conduct further research to identify the molecular mechanisms underlying the development of cetuximab resistance in CRC. In this study, we find that the expressions of many metabolism-related genes are downregulated in cetuximab-resistant CRC cells compared to their sensitive counterparts. Specifically, acetyl-CoA acyltransferase 2 (ACAA2), a key enzyme in fatty acid metabolism, is downregulated during the development of cetuximab resistance. Silencing of ACAA2 promotes proliferation and increases cetuximab tolerance in CRC cells, while overexpression of ACAA2 exerts the opposite effect. RTK-Kras signaling might contribute to the downregulation of ACAA2 expression in CRC, and ACAA2 predicts CRC prognosis in patients with Kras mutations. Collectively, our data suggest that modulating ACAA2 expression contributes to secondary cetuximab resistance in Kras wild-type CRC patients. ACAA2 expression is related to Kras mutation and demonstrates a prognostic role in CRC patients with Kras mutation. Thus, ACAA2 is a potential target in CRC with Kras mutation.

[1]  Shangfeng Yang,et al.  ZNF3 regulates proliferation, migration and invasion through MMP1 and TWIST in colorectal cancer , 2022, Acta biochimica et biophysica Sinica.

[2]  Nnamdi E. Ihuegbu,et al.  ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer , 2022, Nature Communications.

[3]  K. Tsuchihashi,et al.  Inhibition of insulin‐like growth factor‐1 receptor enhances eribulin‐induced DNA damage in colorectal cancer , 2022, Cancer science.

[4]  X. Yang,et al.  ACACB is a novel metabolism-related biomarker in the prediction of response to cetuximab therapy inmetastatic colorectal cancer , 2022, Acta biochimica et biophysica Sinica.

[5]  Wang He,et al.  KRAS mutant–driven SUMOylation controls extracellular vesicle transmission to trigger lymphangiogenesis in pancreatic cancer , 2022, The Journal of clinical investigation.

[6]  C. Ding,et al.  Kif4A mediates resistance to neoadjuvant chemoradiotherapy in patients with advanced colorectal cancer via regulating DNA damage response , 2022, Acta biochimica et biophysica Sinica.

[7]  N. Hay,et al.  A non-catalytic scaffolding activity of hexokinase 2 contributes to EMT and metastasis , 2022, Nature communications.

[8]  Q. Shen,et al.  The critical role of STAT3 in biogenesis of tumor-derived exosomes with potency of inducing cancer cachexia in vitro and in vivo , 2022, Oncogene.

[9]  M. Claussnitzer,et al.  Gaining insight into metabolic diseases from human genetic discoveries. , 2021, Trends in genetics : TIG.

[10]  Tianshu Liu,et al.  Identification of a metabolic signature to predict overall survival for colorectal cancer , 2021, Scandinavian journal of gastroenterology.

[11]  I. Cristea,et al.  The antiviral sirtuin 3 bridges protein acetylation to mitochondrial integrity and metabolism during human cytomegalovirus infection , 2021, PLoS pathogens.

[12]  David A. Knowles,et al.  An integrated approach to identify environmental modulators of genetic risk factors for complex traits , 2021, bioRxiv.

[13]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[14]  J. García-Foncillas,et al.  Vitamin C activates pyruvate dehydrogenase (PDH) targeting the mitochondrial tricarboxylic acid (TCA) cycle in hypoxic KRAS mutant colon cancer , 2021, Theranostics.

[15]  S. Barry,et al.  The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer , 2021, Nature Genetics.

[16]  F. Esposito,et al.  TRAP1 enhances Warburg metabolism through modulation of PFK1 expression/activity and favors resistance to EGFR inhibitors in human colorectal carcinomas , 2020, Molecular oncology.

[17]  H. Clevers,et al.  Hepatocyte growth factor/MET and CD44 in colorectal cancer: partners in tumorigenesis and therapy resistance. , 2020, Biochimica et biophysica acta. Reviews on cancer.

[18]  R. Franco,et al.  AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. , 2020, European journal of cancer.

[19]  J. Berlin,et al.  Combined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer , 2020, Translational oncology.

[20]  F. Ciardiello,et al.  Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed? , 2020, Cancer treatment reviews.

[21]  T. Jiang,et al.  Transcriptomic Analysis of Glioma Based on IDH Status Identifies ACAA2 as a Prognostic Factor in Lower Grade Glioma , 2020, BioMed research international.

[22]  R. Hustinx,et al.  Methylglyoxal Scavengers Resensitize KRAS-Mutated Colorectal Tumors to Cetuximab. , 2020, Cell reports.

[23]  Weiyi Qiu,et al.  PRSS contributes to cetuximab resistance in colorectal cancer , 2020, Science Advances.

[24]  A. Balmain,et al.  KRAS4A Directly Regulates Hexokinase 1 , 2019, Nature.

[25]  Danish Sayed,et al.  Oxoglutarate dehydrogenase and acetyl-CoA acyltransferase 2 selectively associate with H2A.Z-occupied promoters and are required for histone modifications. , 2019, Biochimica et biophysica acta. Gene regulatory mechanisms.

[26]  F. Ciardiello,et al.  Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines , 2019, Journal of experimental & clinical cancer research : CR.

[27]  M. Gerlinger,et al.  Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer , 2018, bioRxiv.

[28]  D. Jäger,et al.  Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial , 2018, British Journal of Cancer.

[29]  C. Leonetti,et al.  Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities , 2018, Journal of experimental & clinical cancer research : CR.

[30]  Jie Zhou,et al.  Identification of a fluorescent small-molecule enhancer for therapeutic autophagy in colorectal cancer by targeting mitochondrial protein translocase TIM44 , 2016, Gut.

[31]  S. Zhang,et al.  Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer. , 2016, Cancer letters.

[32]  A. Bardelli,et al.  Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer , 2016, Clinical Cancer Research.

[33]  Suguru Hasegawa,et al.  Metabolic Alterations Caused by KRAS Mutations in Colorectal Cancer Contribute to Cell Adaptation to Glutamine Depletion by Upregulation of Asparagine Synthetase12 , 2016, Neoplasia.

[34]  N. Copeland,et al.  Two-Step Forward Genetic Screen in Mice Identifies Ral GTPase-Activating Proteins as Suppressors of Hepatocellular Carcinoma. , 2016, Gastroenterology.

[35]  K. Kinzler,et al.  Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer , 2016, Nature Communications.

[36]  A. Bardelli,et al.  The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death , 2016, Nature Medicine.

[37]  F. Rojo,et al.  Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer , 2015, Journal of Translational Medicine.

[38]  R. Salgia,et al.  AXL mediates resistance to cetuximab therapy. , 2014, Cancer research.

[39]  John M. Asara,et al.  Glutamine supports pancreatic cancer growth through a Kras-regulated metabolic pathway , 2013, Nature.

[40]  Enzo Medico,et al.  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.

[41]  Johannes G. Reiter,et al.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.

[42]  Sabine Tejpar,et al.  Implications for KRAS status and EGFR-targeted therapies in metastatic CRC , 2009, Nature Reviews Clinical Oncology.

[43]  A. Lièvre,et al.  Genetics: Predictive value of KRAS mutations in chemoresistant CRC , 2009, Nature Reviews Clinical Oncology.

[44]  P. Harari,et al.  Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members , 2008, Oncogene.

[45]  P. Jeffrey,et al.  Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. , 2005, Cancer cell.

[46]  M. Takiguchi,et al.  Cloning and sequence analysis of a full length cDNA encoding human mitochondrial 3-oxoacyl-CoA thiolase. , 1993, Biochimica et biophysica acta.

[47]  R. Benne,et al.  Nucleotide sequence of human peroxisomal 3-oxoacyl-CoA thiolase. , 1988, Nucleic acids research.

[48]  V. Heinemann,et al.  The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. , 2017, European journal of cancer.

[49]  M. Wiese,et al.  Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  F. McCormick,et al.  Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. , 2013, Cancer discovery.